Source: Lobe Sciences Ltd.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Lobe Sciences (LOBE) updated its corporate presentation describing plans for advancing the development of its psilocin analogues L-130 and L-131
  • highlighting psilocin compounds and development plans
  • Lobe Sciences (LOBE) is a Canadian biopharmaceutical company focused on discovering and developing psychedelic derived medicines for neurologic and brain diseases
  • Lobe Sciences (LOBE) is unchanged today, trading at C$0.06 as of Aug 19, 2022, 2:02 pm ET

Lobe Sciences (LOBE) is updating its corporate presentation describing plans for advancing the development of its psilocin analogues L-130 and L-131.

The corporate presentation highlights its psilocin compounds and development plans.

Philip Young, CEO of Lobe Sciences, stated,

“We have made significant progress toward initiating our first human trials with our proprietary psilocin analog L-130 and pre-clinical plans for L-131.

We believe that Lobe is beginning to be recognized as one of the leading companies developing stable psilocin compounds as noted in leading Biotech publications.

This is an exciting time for all stakeholders and I look forward to continuing to update the investment community as we advance our plans for developing novel drugs for patients around the globe.”

Lobe Sciences (LOBE) is a Canadian biopharmaceutical company focused on discovering and developing psychedelic-derived medicines for neurologic and brain diseases.

Lobe Sciences (LOBE) is unchanged today, trading at C$0.06 as of Aug 19, 2022, 2:02 pm ET.



More From The Market Herald

" Reunion (TSX:REUN) appoints Greg Mayes as President and CEO

Reunion Neuroscience (REUN) (formerly Field Trip Health Ltd.) has appointed Greg Mayes as President and Chief Executive Officer.

" Psyched Wellness (CSE:PSYC) announces successful pilot run & final flavour profile for Calm

Psyched Wellness (PSYC) has announced positive feedback from a pilot run of 300 bottles of Calm.

" Mindset Pharma (CSE:MSET) signs intellectual property license with Cybin (NEO:CYBN)

Mindset Pharma (MSET) announced a licensing agreement allowing Cybin (CYBN) to acquire intellectual property rights for a subset of Mindset’s preclinical compounds.

" Tryp Therapeutics (CSE: TRYP) applies for 2 new provisional patents

Tryp Therapeutics (TRYP) is filing two new provisional patent applications.